Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value

Stock Information for Enzon Pharmaceuticals Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Enzon Pharmaceuticals Inc

Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO
Enzon Pharmaceuticals Announces Results of Rights Offering
Enzon Pharmaceuticals Announces Key Dates for Rights Offering
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting
Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders
OTC Markets Group Welcomes Enzon Pharmaceuticals, Inc. to OTCQX
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Delaware Law by the Board of Enzon Pharmaceuticals Inc.

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.